Sort
4,870 grants matching “glp 1”
BSL-4 Evaluation Core (Core B)
$2,890,889Thomas William Geisbert · University Of Texas Med Br Galveston · U19 · FY2023 · AI
Developing autologous iPSC-RPE based IND for AMD patients
$2,883,025Kapil Bharti · National Eye Institute · ZIA · FY2023 · EY
Enhancing Chimeric Antigen Receptor T Cell Therapies for HematologicMalignancies: Beyond CART 19
$2,863,199Carl H. June · University Of Pennsylvania · P01 · FY2025 · CA
Inhaled GM-CSF Therapy of Autoimmune Pulmonary Alveolar Proteinosis
$2,853,144Sharie Haugabook · National Center For Advancing Translational Sciences · ZIA · FY2017 · TR
Developing autologous iPSC-RPE based IND for AMD patients
$2,850,386Kapil Bharti · National Eye Institute · ZIA · FY2016 · EY
Development of a 3-month implantable depot pellet of Naltrexone for the treatment of Opioid Use Disorder.
$2,842,430Balbir Brar · Biocorrx, Inc. · UG3 · FY2019 · DA
Development of a 3-month implantable depot pellet of Naltrexone for the treatment of Opioid Use Disorder.
$2,831,838Andrew Peter Mallon · Biocorrx, Inc. · UG3 · FY2020 · DA
Multi Site Randomized Trial of a GLP-1/GIP Receptor Agonist for Smoking Cessation
$2,828,440Christian S Hendershot · University Of Southern California · U01 · FY2025 · DA
Scientific Core - Compound Optimization and Prioritization.
$2,822,282Anna Upton · Global Alliance For Tb Drug Development · U19 · FY2023 · AI
Enhancing Chimeric Antigen Receptor T Cell Therapies for Hematologic Malignancies: Beyond CART 19
$2,804,200Carl H. June · University Of Pennsylvania · P01 · FY2018 · CA
Role of G protein-coupled receptors in regulating glucose and energy homeostasis
$2,783,564Jurgen Wess · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2019 · DK
Enhancing Chimeric Antigen Receptor T Cell Therapies for HematologicMalignancies: Beyond CART 19
$2,782,255Carl H. June · University Of Pennsylvania · P01 · FY2023 · CA
Enhancing Chimeric Antigen Receptor T Cell Therapies for Hematologic Malignancies: Beyond CART 19
$2,756,111Carl H. June · University Of Pennsylvania · P01 · FY2019 · CA
RP1: rVSV Vectored Vaccine to Treat Ebola and Marburg Infection
$2,733,163John H Eldridge · University Of Texas Med Br Galveston · U19 · FY2016 · AI
GENERAL CLINICAL RESEARCH CENTER
$2,704,143Thomas F Boat · Cincinnati Childrens Hosp Med Ctr · M01 · FY2006 · RR
Clinical Psychoneuroendocrinology and Neuropsychopharmacology (CPN)
$2,696,667Lorenzo Leggio · National Institute On Drug Abuse · ZIA · FY2025 · DA
Development of PPL-138, a Novel Mixed NOP/Mu Partial Agonist for Treatment of CocaineUse Disorder
$2,680,161Lawrence R Toll · Phoenix Pharmalabs, Inc. · U01 · FY2022 · DA
BSL-4 Evaluation Core (Core B)
$2,665,747Thomas William Geisbert · University Of Texas Med Br Galveston · U19 · FY2019 · AI
Developing autologous iPSC-RPE based IND for AMD patients
$2,655,942Kapil Bharti · National Eye Institute · ZIA · FY2021 · EY
BSL-4 Evaluation Core (Core B)
$2,655,768Thomas William Geisbert · University Of Texas Med Br Galveston · U19 · FY2020 · AI
Scientific Core - Compound Optimization and Prioritization.
$2,652,211Anna Upton · Global Alliance For Tb Drug Development · U19 · FY2021 · AI
Thin, High-Density, High-Performance, Depth and Surface Microelectrodes for Diagnosis and Treatment of Epilepsy
$2,625,782Shadi Dayeh · University Of California, San Diego · UG3 · FY2024 · NS
General Clinical Research Center
$2,625,723Arnold W Strauss · Cincinnati Childrens Hosp Med Ctr · M01 · FY2007 · RR
NATIONAL GENE VECTOR LABORATORY
$2,622,303Indiana Univ-Purdue Univ At Indianapolis · U42 · FY2000 · RR
Xenobiotic receptors
$2,609,568Frank J Gonzalez · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA